Pfizer presents results from the Phase 3 BASIS study on HYMPAVZI

Pfizer (PFE) presented results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no treatment-related lab monitoring. The study found: statistically significant and clinically meaningful 93% reduction in mean treated annualized bleeding rate, demonstrating superiority of HYMPAVZI over OD therapy; Superiority of HYMPAVZI was also demonstrated across all bleeding-related secondary endpoints – spontaneous bleeds; After six months in the ATP, HYMPAVZI demonstrated superiority and/or numerical improvement on health-related quality-of-life outcomes compared to OD therapy. HYMPAVZI was generally well tolerated.